Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 904-912

  Hussain, Maha ^a   Carducci, Michael A ^b   Slovin, Susan ^c   Cetnar, Jeremy ^d,f   Qian, Jiang ^e   McKeegan, Evelyn M ^e   Refici Buhr, Marion ^e   Chyla, Brenda ^e   Shepherd, Stacie P ^e   Giranda, Vincent L ^e   Alumkal, Joshi J ^f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e ABBVIE INC   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Combination therapy; Metastatic castration resistant prostate cancer; Pilot study; Temozolomide; Veliparib

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TEMOZOLOMIDE; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DACARBAZINE; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; DNA REPAIR; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; DACARBAZINE; DNA REPAIR; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PILOT PROJECTS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

EID: 84919920835     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0099-0     Document Type: Article

References (41)

1. Dantzer F, de La Rubia G, Ménissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V (2000) Base excision repair is impaired in mammalian cells lacking poly (ADP-ribose) polymerase-1. Biochemistry 39(25):7559-69
2. Schreiber V, Amé JC, Dollé P et al (2002) Poly (ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277(25):23028-36
3. Annunziata CM, O'Shaughnessy J (2010) Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 16(18):4517-26
4. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T (1991) Enhanced expression of poly (ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 37(4):223-7
5. Shiobara M, Miyazaki M, Ito H et al (2001) Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16(3):338-44
6. de Murcia JM, Niedergang C, Trucco C et al (1997) Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 94(14):7303-7
7. Masutani M, Nozaki T, Nakamoto K et al (2000) The response of Parp knockout mice against DNA damaging agents. Mutat Res 462(2-3):159-66
8. de Murcia MJ, Ricoul M, Tartier L (2003) Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 22(9):2255-63
9. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-34
10. Fong PC, Yap TA, Boss DS et al (2010) Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28(15):2512-9
11. Tutt A, Robson M, Garber JE et al (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235-44
12. Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737):245-51
13. Plummer R, Jones C, Middleton M et al (2008) Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14(23):7917-23
14. Kummar S, Ji J, Morgan R et al (2012) A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 18(6):1726-34
15. Schiewer MJ, Goodwin JF, Han S et al (2012) Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2(12):1134-49
16. Penning TD, Zhu G-D, Gandhi VB et al (2009) Discovery of the poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52(2):514-23
17. Kummar S, Kinders R, Gutierrez ME et al (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27(16):2705-11
18. Li X, Delzer J, Voorman R, de Morais SM, Lao Y (2011) Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly (ADP-ribose) polymerase. Drug Metab Dispos 39(7):1161-69
19. Barreto-Andrade JC, Efimova EV, Mauceri HJ et al (2011) Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther 10(7):1185-93
20. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG (2008) A novel poly (ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 88(2):258-68
21. Palma JP, Wang YC, Rodriguez LE et al (2009) ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 15(23):7277-90
22. Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13(9):2728-37
23. Palma JP, Rodriguez LE, Bontcheva-Diaz VD et al (2008) The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 28(5A):2625-35
24. Molina JR ND, Erlichman C, Lensing JL, Luo Y, Giranda V. Ongoing Phase 1 Studies of a Novel PARP Inhibitor, ABT-888: Pharmacokinetics, Safety and Anti-Tumor Activity [abstract]. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research. 2009 Apr 18-22; Denver, CO. AACR; 2009. Abstract nr 3602.
25. Petrylak DP, Ankerst DP, Jiang CS et al (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98(8):516-21
26. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst 92(3):205-16
27. Rudin CM, Hann CL, Garon EB et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163-9
28. Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781-91
29. Gandhi L, Camidge DR (2011) Ribeiro de Oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29(7):909-16
30. Shaffer DR, Leversha MA, Danila DC et al (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13(7):2023-9
31. Scher HI, Jia X, de Bono JS et al (2009) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10(3):233-9
32. Locker GY, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313-27
33. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8(7):497-511
34. Tomlins SA, Rhodes DR, Perner S et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644-8
35. Brenner JC, Ateeq B, Li Y et al (2011) Mechanistic rationale for inhibition of poly (ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19(5):664-78
36. Haffner MC, Aryee MJ, Toubaji A et al (2010) Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 42(8):668-75
37. van Brussel JP, Busstra MB, Lang MS, Catsburg T, Schröder FH, Mickisch GH (2000) A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 45(6):509-12
38. Panteleakou Z, Lembessis P, Sourla A et al (2009) Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 15(3-4):101-14
39. Doyen J, Alix-Panabières C, Hofman P et al (2012) Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Crit Rev Oncol Hematol 81(3):241-56
40. Feuer JA, Lush RM, Venzon D et al (1998) Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer. J Investig Med 46(2):66-72
41. Haffner MC, De Marzo AM, Meeker AK, Nelson WG, Yegnasubramanian S (2011) Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer Res 17(12):3858-64